227 related articles for article (PubMed ID: 18215014)
1. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
Wu X; Ohrngren P; Ekegren JK; Unge J; Unge T; Wallberg H; Samuelsson B; Hallberg A; Larhed M
J Med Chem; 2008 Feb; 51(4):1053-7. PubMed ID: 18215014
[TBL] [Abstract][Full Text] [Related]
2. Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Ginman N; Johansson A; Wallberg H; Larhed M; Samuelsson B; Unge T; Hallberg A
J Med Chem; 2006 Mar; 49(5):1828-32. PubMed ID: 16509598
[TBL] [Abstract][Full Text] [Related]
3. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
[TBL] [Abstract][Full Text] [Related]
5. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
7. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
[TBL] [Abstract][Full Text] [Related]
9. Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Gising J; Wallberg H; Larhed M; Samuelsson B; Hallberg A
Org Biomol Chem; 2006 Aug; 4(16):3040-3. PubMed ID: 16886068
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
11. 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Degoey DA; Grampovnik DJ; Flentge CA; Flosi WJ; Chen HJ; Yeung CM; Randolph JT; Klein LL; Dekhtyar T; Colletti L; Marsh KC; Stoll V; Mamo M; Morfitt DC; Nguyen B; Schmidt JM; Swanson SJ; Mo H; Kati WM; Molla A; Kempf DJ
J Med Chem; 2009 Apr; 52(8):2571-86. PubMed ID: 19323562
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
13. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Tamamura H; Koh Y; Ueda S; Sasaki Y; Yamasaki T; Aoki M; Maeda K; Watai Y; Arikuni H; Otaka A; Mitsuya H; Fujii N
J Med Chem; 2003 Apr; 46(9):1764-8. PubMed ID: 12699395
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
Joshi A; Véron JB; Unge J; Rosenquist Å; Wallberg H; Samuelsson B; Hallberg A; Larhed M
J Med Chem; 2013 Nov; 56(22):8999-9007. PubMed ID: 24160253
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
16. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
18. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Martin JL; Begun J; Schindeler A; Wickramasinghe WA; Alewood D; Alewood PF; Bergman DA; Brinkworth RI; Abbenante G; March DR; Reid RC; Fairlie DP
Biochemistry; 1999 Jun; 38(25):7978-88. PubMed ID: 10387041
[TBL] [Abstract][Full Text] [Related]
19. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
